Aleje Jerozolimskie 65/79, 00-697 Warsaw, Poland

Injectable Anticoagulants Market : By Type, Application, Size, Growth, Analysis & Forecast 2026


Injectable Anticoagulants Market : By Type, Application, Size, Growth, Analysis & Forecast 2026

Press Release

Anticoagulants help control the adhering of platelets and stop clotting proteins from binding together. These are commonly used in the prevention and treatment of venous thrombosis, pulmonary embolism, and other conditions of blood clotting. Injectable anticoagulants are administered via different routes of injectable drug delivery and are categorized into direct thrombin inhibitors, factor Xa inhibitors, heparins, low-molecular-weight heparin (LMWH) including dalteparin, enoxaparin, and others. Heparin is an injectable anticoagulant widely used in hospitals for rapid anticoagulation. LMWHs are highly acceptable and preferred over heparins, as LMWHs can be self-administered when used in home settings, while heparins are large sized molecules and bleeding is associated with its use. Hence, these can only be injected at hospitals through skilled professionals.

View Report:

According to the World Health Organization (WHO), prolonged traveling by passengers via automobile, train, or airplane for more than four hours increases the risk of developing venous thromboembolism. Coagulation disorders such as venous thromboembolism (VTE), which includes both deep vein thrombosis and pulmonary embolism, affect nearly 1 million people in the U.S. each year. According to the Centers for Disease Control and Prevention, 500,000 to 900,000 people in the U.S. are affected by VTE each year. A study published by Deutsches Arzteblatt International in 2013 revealed that the annual incidence rate of diagnosed VTE in Germany stood at 150 to 200 cases per 100,000. The statistics above clearly indicate the demand for safe, reliable, and affordable anticoagulants.

Rise in incidence of coagulation and renal and heart diseases, commercialization of safe and cost-effective biological origin anti-coagulants, enhanced quality control measures, increase in geriatric population, and surge in investment in research and development of biological origin drugs drive the market. High cost of treatment is the only factor restraining the market.

Request a Brochure of the Report @

The global injectable anticoagulants market can be segmented based on drug type, application, and distribution channel. In terms of drug type, the market can be categorized into low-molecular-weight heparin (LMWH) and direct thrombin inhibitors (DTI). The low-molecular-weight heparin segment accounted for the largest market share and is expected to witness rapid growth during the forecast period. Based on application, the injectable anticoagulants market can be classified into venous thromboembolism (VTE), atrial fibrillation, acute coronary syndrome, and myocardial infarction. In terms of distribution channel, the global market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for the largest market share and the trend is likely to continue during the forecast period owing to rise in prevalence of deep vein thrombosis and increase in hospital inpatients for different disease treatments. This, in turn, is likely to drive the global injectable anticoagulants market during the forecast period.

Geographically, the global injectable anticoagulants market can be segmented into five major regions: North America, Middle East & Africa, Latin America, Asia Pacific, and Europe. North America is the leading market for injectable anticoagulants in terms of revenue, followed by Europe. The U.S. held the largest share of the market in North America, followed by Canada. The injectable anticoagulants market in Asia Pacific is likely to expand at a high CAGR during the forecast period. This is attributed to increase in patient population and rise in incidence of chronic diseases, which has led to high demand for injectable anticoagulant products.

Request TOC @

Key players operating in the global injectable anticoagulants market include Sanofi, Genentech (Roche), Boehringer Ingelheim, Pfizer, The Medicines Company, B. Braun Melsungen AG, Baxter, Aspen Otsuka, Fresenius SE & Co. KGaA, LEO Pharma A/S, and Sagent Pharmaceuticals, Inc.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: [email protected]